Viralclear expands ongoing phase 2 trial size for its oral anti-viral for treatment of covid-19

Viralclear expands ongoing phase 2 trial size for its oral anti-viral for the treatment of covid-19, expands trial locations and appoints contract manufacturing organization to manufacture phase 3 supplies of merimepodib oral solution.biosig technologies inc - size of ongoing phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects.biosig technologies inc - added 2 new principal investigators for ongoing phase 2 trial expanding total number of locations to 10.biosig technologies inc - cmo appointed to manufacture phase 3 supplies of merimepodib oral solution.biosig technologies inc - merimepodib monotherapy trial to be conducted in outpatient setting after current combination trial completes.biosig technologies- once additional subjects are enrolled, further clinical data is got, team to discuss with fda appropriate size for phase 3 trial.
BSGM Ratings Summary
BSGM Quant Ranking